SCHEMBL4147196

SCHEMBL4147196

CC(C)c1csc(NC(=O)C(F)(F)F)c1C(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ANO1 Q5XXA6 11/20 0.53
MAPT P10636 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
TP53 P04637 3/20 0.44
PDK1 Q15118 1/20 0.41
PDK2 Q15119 1/20 0.41
PDK3 Q15120 1/20 0.41
PDK4 Q16654 1/20 0.41
ANO2 Q9NQ90 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
CRHBP P24387 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
CRHR2 Q13324 1/20 0.41
MAPK1 P28482 1/20 0.41
BLM P54132 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4150347 0.86 ANO1 (0.41) ANO1MAPTSMN1; SMN2TP53ANO2
SCHEMBL4135342 0.86 BRD4 (0.49) ANO1MAPTSMN1; SMN2TP53MEN1
SCHEMBL4149999 0.80 KMT2A (0.50) MAPTSMN1; SMN2TP53MEN1HTT
SCHEMBL4146082 0.79 ANO1 (0.36) ANO1MAPTSMN1; SMN2TP53ANO2
SCHEMBL4141063 0.79 ABCC1 (0.56) ANO1MAPTSMN1; SMN2MEN1ALDH1A1
SCHEMBL4135317 0.75 ANO1 (0.53) ANO1MAPTSMN1; SMN2PDK1PDK2
SCHEMBL5260503 0.74 ANO1 (0.50) ANO1MAPTSMN1; SMN2TP53PDK1
SCHEMBL4150055 0.73 ABCC1 (0.40) MAPTTP53MEN1ALDH1A1LMNA
SCHEMBL8388485 0.72 ABCC1 (0.36) ANO1MAPTSMN1; SMN2TP53ANO2
SCHEMBL5550330 0.72 HDAC1 (0.67) ANO1MAPTTP53PDK1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-06-04 US claimed
EP-1802634-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-07-04 EP claimed
WO-2006044826-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO claimed
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-06-04 US disclosed
EP-1802634-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-07-04 EP disclosed
WO-2006044826-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents TP53, BRDT, VHL ANO1 3854/4885MAPT 1629/4885SMN1; SMN2 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.